According to a recent study published by Future Market Insights, the global PD1 non-small cell lung cancer treatment market size is slated to reach a valuation of US$ 26.96 Billion in 2023, and will further increase to US$ 61 Billion, registering a CAGR of 8.51% from 2023 to 2033. Rising prevalence of non-small cell lung cancer is anticipated to drive market growth during the forecast period. The increasing prevalence of cancer is the key factor for the growth of PD-1 non-small cell lung cancer treatment market along with the technological innovations and advancements in cancer screening procedures that are expected to surge market growth. In addition, increased public awareness, greater government initiatives to fight cancer, and rising healthcare expenses are expected to boost the market ahead.
High efficacy and superior treatment outcome-based PD-1/PD-L1 inhibitors are on high demand in severe cancer treatments. In addition, extended indications of existing immunotherapies are expected to create huge demand for the cancer treatments and offer new growth opportunity in the market. Recent approvals of new drugs are expected to augment market growth during the forecast period. In February 2022, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved Genentech’s Tecentriq to treat early-stage non-small cell lung cancer.
Request A Sample Copy of This Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16404
Similarly, in October 2021, the United States Food and Drug Administration (USFDA) approved atezolizumab (Tecentriq, Genentech, Inc.) in the United States for stage II and IIIA non-small cell lung cancer patients. In March 2021, the FDA approved Pfizer’s Lorbrena (lorlatinib) to treat ALK-positive NSCLC patients in the United States. Additionally, in October 2021, Ventana Medical Systems, Inc. received United States FDA approval for VENTANA PD-L1 (SP263) Assay as a companion diagnostic device to select patients for Tecentriq. Hence, recent new drug approvals and the launch of companion diagnostics to select targeted patients are responsible for the growth of the market during the forecast period.
Key Takeaways from the Market Study:
- North America is expected to dominate the market with a market share of 42% during the forecast period.
- South Asia is estimated to reflect highest CAGR of 8% during the forecast period.
- The product demand in China will witness a CAGR of 13.7% by 2033.
- By treatment type, targeted therapy is projected to rule the market with an estimated valuation of US$ 31.7 Billion by end of the forecast period.
- By distribution channel, Hospital segment will grow with CAGR of 12% during the period of assessment.
Fast approval of new drugs and launch of companion diagnostics will propel the demand for PD1 Non-small cell lung cancer treatment- comments an FMI Analyst
Click Here to Request Methodology: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16404
Competitive Landscape:
The market is fragmented and moderately competitive. The strategies like mergers and acquisitions adopted by major market players will boost market growth.
Key Companies Profiled:
- Merck Co. & Inc.
- Bristol-Myers Squibb
- F. Hoffmann-La Roche AG
- AstraZeneca Plc.
- Pfizer Inc.
- Novartis AG
- GlaxoSmithKline Plc.
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Sanofi
- Agennix AG
Some recent developments in this industry are:
- In January 2021, The Lung Ambition Alliance, which is a global coalition with the bold ambition to eliminate lung cancer as a cause of death, started The Initiatives in Lung Cancer Care (ILC2) program. The aim of the program is to fund projects that drive measurable improvements across the patient journey, from early detection to palliative care or survivorship.
- In August 2022, the Food and Drug Administration granted regular approval to capmatinib (Tabrecta, Novartis Pharmaceuticals Corp.) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.
- In March 2022, Regeneron and BioNTech expanded their collaboration agreement for the development of Libtayo and FixVac (cemiplimab) Combination to treat advanced NSCLC.
- In 2021, Daiichi Sankyo received FDA approval for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma.
Get a Purchase on the Report: https://www.futuremarketinsights.com/checkout/16404
Key Segments Profiled in the PD1 Non-small Cell Lung Cancer Treatment Market Industry survey:
By Drug Type:
- Nivolumab
- Pembrolizumab
- Atezolizumab
- Avelumab
- Durvalumab
By Cancer Type:
- Squamous Cell carcinoma
- Adenocarcinoma
- Large-cell carcinoma
By Treatment:
- Chemotherapy
- Targeted therapy
- Immunotherapy
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
